About
BioEclipse develops allogeneic and autologous immunotherapies that program immune cells to attack resistant and recurrent solid tumors while stimulating the patient's immune system.
Explore BioEclipse's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.